SG149001A1 - N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b - Google Patents
N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein bInfo
- Publication number
- SG149001A1 SG149001A1 SG200809026-8A SG2008090268A SG149001A1 SG 149001 A1 SG149001 A1 SG 149001A1 SG 2008090268 A SG2008090268 A SG 2008090268A SG 149001 A1 SG149001 A1 SG 149001A1
- Authority
- SG
- Singapore
- Prior art keywords
- apolipoprotein
- inhibitors
- piperidine substituted
- aryl piperidine
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03104601 | 2003-12-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG149001A1 true SG149001A1 (en) | 2009-01-29 |
Family
ID=34684566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG200809026-8A SG149001A1 (en) | 2003-12-09 | 2004-12-06 | N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8772494B2 (fr) |
| EP (1) | EP1694644B1 (fr) |
| JP (1) | JP4790626B2 (fr) |
| KR (1) | KR101125120B1 (fr) |
| CN (1) | CN100548985C (fr) |
| AT (1) | ATE548350T1 (fr) |
| AU (1) | AU2004299295B2 (fr) |
| BR (1) | BRPI0417469B8 (fr) |
| CA (1) | CA2547243C (fr) |
| EA (1) | EA009081B1 (fr) |
| ES (1) | ES2383179T3 (fr) |
| IL (1) | IL176171A (fr) |
| NO (1) | NO337251B1 (fr) |
| NZ (1) | NZ546964A (fr) |
| SG (1) | SG149001A1 (fr) |
| UA (1) | UA83510C2 (fr) |
| WO (1) | WO2005058824A2 (fr) |
| ZA (1) | ZA200604718B (fr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007053436A1 (fr) * | 2005-10-31 | 2007-05-10 | Janssen Pharmaceutica N.V. | Piperazines et piperidines substituees en tant que modulateurs du recepteur du neuropeptide y2 |
| US9101160B2 (en) | 2005-11-23 | 2015-08-11 | The Coca-Cola Company | Condiments with high-potency sweetener |
| ES2569558T3 (es) | 2006-04-03 | 2016-05-11 | Roche Innovation Center Copenhagen A/S | Composición farmacéutica que comprende oligonucleótidos antisentido anti-ARNmi |
| MX2008012219A (es) | 2006-04-03 | 2008-10-02 | Santaris Pharma As | Composicion farmaceutica que comprende oligonucleotidos antisentido anti-miarn. |
| US8017168B2 (en) | 2006-11-02 | 2011-09-13 | The Coca-Cola Company | High-potency sweetener composition with rubisco protein, rubiscolin, rubiscolin derivatives, ace inhibitory peptides, and combinations thereof, and compositions sweetened therewith |
| US8470791B2 (en) | 2007-03-22 | 2013-06-25 | Santaris Pharma A/S | RNA antagonist compounds for the inhibition of Apo-B100 expression |
| WO2008113832A2 (fr) | 2007-03-22 | 2008-09-25 | Santaris Pharma A/S | Composés arn antagonistes courts pour la modulation de l'arnm cible |
| AU2008306327B2 (en) | 2007-10-04 | 2014-05-15 | Roche Innovation Center Copenhagen A/S | Micromirs |
| US8404659B2 (en) | 2008-03-07 | 2013-03-26 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of MicroRNA related diseases |
| ES2541442T3 (es) | 2008-08-01 | 2015-07-20 | Roche Innovation Center Copenhagen A/S | Modulación mediada por microARN de factores estimulantes de colonias |
| WO2010122538A1 (fr) | 2009-04-24 | 2010-10-28 | Santaris Pharma A/S | Compositions pharmaceutiques pour le traitement de patients souffrant du vhc ne réagissant pas aux interférons |
| EP2456870A1 (fr) | 2009-07-21 | 2012-05-30 | Santaris Pharma A/S | Oligomères anti-sens ciblant pcsk9 |
| MX391977B (es) | 2013-06-27 | 2025-03-21 | Roche Innovation Ct Copenhagen As | Oligómeros antisentido y conjugados con diana en la proteína-convertasa subtilisina/kexina tipo 9(pcsk9). |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9826412D0 (en) * | 1998-12-03 | 1999-01-27 | Glaxo Group Ltd | Chemical compounds |
| GB0013383D0 (en) | 2000-06-01 | 2000-07-26 | Glaxo Group Ltd | Therapeutic benzamide derivatives |
| GB0013378D0 (en) * | 2000-06-01 | 2000-07-26 | Glaxo Group Ltd | Use of therapeutic benzamide derivatives |
| JO2654B1 (en) * | 2000-09-04 | 2012-06-17 | شركة جانسين فارماسوتيكا ان. في | Multiple aryl caroxa amides are useful as lipid - lowering agents |
| JO2390B1 (en) | 2001-04-06 | 2007-06-17 | شركة جانسين فارماسوتيكا ان. في | Diphenylcarboxamides act as lipid-lowering agents |
| GB0109287D0 (en) * | 2001-04-12 | 2001-05-30 | Glaxo Group Ltd | Therapeutic benzamide derivatives |
| GB0129015D0 (en) | 2001-12-04 | 2002-01-23 | Glaxo Group Ltd | Compounds |
| UA79300C2 (en) * | 2002-08-12 | 2007-06-11 | Janssen Pharmaceutica Nv | N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b secretion |
-
2004
- 2004-06-12 UA UAA200605783A patent/UA83510C2/uk unknown
- 2004-12-06 CA CA2547243A patent/CA2547243C/fr not_active Expired - Fee Related
- 2004-12-06 EP EP04804685A patent/EP1694644B1/fr not_active Expired - Lifetime
- 2004-12-06 AT AT04804685T patent/ATE548350T1/de active
- 2004-12-06 US US10/580,530 patent/US8772494B2/en not_active Expired - Fee Related
- 2004-12-06 WO PCT/EP2004/053280 patent/WO2005058824A2/fr not_active Ceased
- 2004-12-06 AU AU2004299295A patent/AU2004299295B2/en not_active Ceased
- 2004-12-06 BR BRPI0417469A patent/BRPI0417469B8/pt not_active IP Right Cessation
- 2004-12-06 JP JP2006543538A patent/JP4790626B2/ja not_active Expired - Fee Related
- 2004-12-06 CN CNB2004800362613A patent/CN100548985C/zh not_active Expired - Fee Related
- 2004-12-06 NZ NZ546964A patent/NZ546964A/en not_active IP Right Cessation
- 2004-12-06 EA EA200601120A patent/EA009081B1/ru not_active IP Right Cessation
- 2004-12-06 ES ES04804685T patent/ES2383179T3/es not_active Expired - Lifetime
- 2004-12-06 KR KR1020067013049A patent/KR101125120B1/ko not_active Expired - Fee Related
- 2004-12-06 SG SG200809026-8A patent/SG149001A1/en unknown
-
2006
- 2006-06-07 IL IL176171A patent/IL176171A/en active IP Right Grant
- 2006-06-08 ZA ZA200604718A patent/ZA200604718B/en unknown
- 2006-07-04 NO NO20063103A patent/NO337251B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0417469A (pt) | 2007-04-10 |
| ATE548350T1 (de) | 2012-03-15 |
| WO2005058824A2 (fr) | 2005-06-30 |
| ZA200604718B (en) | 2007-10-31 |
| US20070099934A1 (en) | 2007-05-03 |
| NO20063103L (no) | 2006-09-05 |
| JP4790626B2 (ja) | 2011-10-12 |
| AU2004299295B2 (en) | 2010-07-15 |
| IL176171A (en) | 2013-08-29 |
| ES2383179T3 (es) | 2012-06-18 |
| CA2547243C (fr) | 2012-10-23 |
| EP1694644B1 (fr) | 2012-03-07 |
| CA2547243A1 (fr) | 2005-06-30 |
| WO2005058824A3 (fr) | 2005-10-27 |
| US8772494B2 (en) | 2014-07-08 |
| EA009081B1 (ru) | 2007-10-26 |
| UA83510C2 (en) | 2008-07-25 |
| HK1100559A1 (zh) | 2007-09-21 |
| IL176171A0 (en) | 2006-10-05 |
| KR20060111628A (ko) | 2006-10-27 |
| NO337251B1 (no) | 2016-02-22 |
| KR101125120B1 (ko) | 2012-03-21 |
| EP1694644A2 (fr) | 2006-08-30 |
| EA200601120A1 (ru) | 2006-10-27 |
| CN1890217A (zh) | 2007-01-03 |
| JP2007513921A (ja) | 2007-05-31 |
| NZ546964A (en) | 2009-03-31 |
| BRPI0417469B1 (pt) | 2019-06-25 |
| AU2004299295A1 (en) | 2005-06-30 |
| BRPI0417469B8 (pt) | 2021-05-25 |
| CN100548985C (zh) | 2009-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY136632A (en) | N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b secretion | |
| SE0200920D0 (sv) | Novel compounds | |
| HUP0303876A3 (en) | Preparation of pharmaceutical compositions for treatment of type 2 diabetes using piperidine or tiazolidine, inhibitors of dipeptidyl peptidase iv | |
| WO2007060140A3 (fr) | Inhibiteurs de diacylglycérol acyltransférase (dgat) | |
| IL187005A0 (en) | Diacylglycerol acyltransferase inhibitors | |
| TW200613243A (en) | Novel compounds | |
| SE0300480D0 (sv) | Novel compounds | |
| DK1506185T3 (da) | Forbindelser og deres anvendelse som 5-HT-inhibitorer | |
| CY1109962T1 (el) | Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4,5]δεκαν-2-ονης για τη θεραπεια παχυσαρκιας | |
| JO2390B1 (en) | Diphenylcarboxamides act as lipid-lowering agents | |
| JO2409B1 (en) | Second-phenyl carboxy amides are useful as lipid-lowering agents | |
| SG149001A1 (en) | N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b | |
| ATE386725T1 (de) | Heterocyclylverbindungen | |
| NO20050073L (no) | Ringsubstituerte difenylazetidinoner, deres fremstilling, deres anvendelse samt legemidler inneholdende forbindelsene | |
| DE602004008959D1 (de) | Benzoäbüä1,4üdioxepinderivate | |
| TW200806311A (en) | Neuropeptide-2 receptor-agonists | |
| DK1511489T3 (da) | Nye farmaceutiske sammensætninger indeholdende flibanserin-polymorf A | |
| GB0109122D0 (en) | Novel compounds | |
| TW200626553A (en) | Novel compounds | |
| SE0401763D0 (sv) | Compounds | |
| AU2001246999A1 (en) | New neurokinin antagonists for use as medicaments | |
| EA200870223A1 (ru) | Производные бензоизоиндола для лечения боли | |
| MY139613A (en) | Novel piperazinyl-pyrazinone derivatives for the treatment of 5-ht2a receptor-related disorders | |
| AU2001244999A1 (en) | Naphthamide neurokinin antagonists for use as medicaments | |
| JO2529B1 (en) | Ariel pybradine is a substitute for phenyl carboxymides |